Loading

JSM Chemistry

Evaluating the Basis for NK Sensitivity and NK Resistance in Prototypic NK Sensitive and Resistant Cell Line

Research Article | Open Access

  • 1. Department of Biotechnology, Delhi Technological University, India
+ Show More - Show Less
Corresponding Authors
Asmita Das, Department of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Main Bawana Road
Abstract

Tumors develop numerous mechanisms through which they evade NK cell attack. Several molecules secreted by YAC-1 cells and P815 cells were evaluated for their interaction with NK cell receptors. The affinity characterization of NK cell receptor with tumor expressed ligands will help in understanding the binding patterns required for the activation of NK cell activity. A detailed understanding of the mechanisms of tumor evasion and tumor susceptibility in the tumor microenvironment is essential for developing effective cancer therapies. The multi-faceted recognition pattern of tumor derived factors by NK activating receptors and every accessible surface involved in this binding event has been explored. Interaction between the known factors (galactin-3, CD63 (AD1 antigen), gp70 and p30) present on the surface membrane of mastocytoma P815 cell with NK inhibitory receptor Ly49A on NK cell was explored for evaluating the basis for tumor resistance to NK mediated lysis and interaction between T-cell lymphoma YAC-1 cell derived ligands(p30CA, p12, p15MA and p15E) with NK activating receptor Ly49H was evaluated for potential basis for NK susceptibility by YAC cells addressed by computational approaches which further help to develop NK based cancer therapeutic strategies (Graphic 1).

Keywords


•    P815 cell
•    Natural killer cells receptors
•    YAC-1 cells
•    Ligand interactions

Citation

Mishra R, Verma R, Shreni S, Kaur J, Joshi D, et al. (2016) Evaluating the Basis for NK Sensitivity and NK Resistance in Prototypic NK Sensitive and Resistant Cell Line. JSM Chem 4(4): 1035

INTRODUCTION

NK cells are large, granular, cytotoxic lymphocytes of innate immune system. NK cells have natural capacity to kill tumor cell. They do not require any prior antigenic sensitization and is capable of dealing with a broad range of virus infected cells and tumor cells. NK cell activation and function are strongly influenced by the interplay of inhibitory and activating signals [1].

Tumor cells have evolved various mechanisms by which they can evade NK cell attack. These mechanisms include interference of NK cell activation, inducing inhibition as well as modulation of NK receptor expression pattern and thus regulating NK cell function. Tumor derived factors may cause modulation of costimulation, adhesion or susceptibility to apoptosis [2].

NK cells recognize target cells in two different ways i.e. lack of MHC-class I expression and absence of expression of appropriate ligands for NK cell receptor which renders target cells susceptible to NK mediated lysis. NK cell receptors utilize several parallel recognition patterns that enable them to distinguish between abnormal cell and healthy cell.

YAC-1 is a murine T-cell lymphoma cell line which is susceptible to NK-mediated killing. MHC-I molecule is a ligand for inhibitory receptors on NK cells [3], thus causing susceptibility of YAC-1 cells to NK cell cytotoxicity, while P815, which is a mastocytoma cell line expresses reduced activating ligands. Inhibitory receptor present on NK cells MHC molecule and upon engagement of these receptors, block the ability of NK cells to attack target cells, hence if inhibitory ligand is not present on the target cell, NK cell will cause lysis of the target cell.

However in the present study we tried to explore if in the addition to modulation of MHC I (ligand for inhibitory receptor) direct binding to tumor expressed ligand with other NK inhibitory or activating receptors do indeed play a role in NK resistance and susceptibility.

Structure of various ligands expressed on YAC-1 and P815 cell were modeled using Phyre 2 and molecular docking was performed using PATCHDOCK between YAC-1 ligands (namely, p30CA,p12,p15MA and p15E) and NK activating receptor, Ly49H,similarly P815 ligands (namely, galectin-3, CD63, gp70 and p30) were studied for molecular docking with NK inhibitory receptor Ly49A.

In the present study we tried to elucidate the molecular basis of susceptibility of YAC tumor cells and resistance of P815 cells to NK mediated cytotoxicity. YAC 1 cells express low level of MHC I (ligand for inhibitory receptors on NK) and P815 cells on the other hand express high level of MHC I molecules thus causing susceptibility of YAC and resistance of P815 to NK mediated cytolysis. However, in the present study in addition to above expression pattern of MHC I, we show direct binding efficiency of tumor expressed ligands with activating and inhibitory NK receptors. Furthermore, D-complex energy was calculated and some significant interaction between ligand and receptor, which highlighted the binding pattern required for the activation of NK cell effecter function has been reported in present study.

MATERIAL AND METHODS

Receptor Modeling

Ly49H: A 265 amino acid sequence of Ly49H of mouse origin was retrieved from NCBI (accession no. = AAR03586.1) and Ly49A: A 262 amino acid sequence of Ly49A of mouse origin was retrieved from NCBI (accession no = AAF99547.1). Since the crystal structure of Ly49H and Ly49A was not available, the protein was modeled using a hybrid modeling server named Phyre2. The platform incorporates ab initio folding simulation called Poing 2to model regions of proteins with no detectable homology to the known structure [4-6].

Ligand preparation

Ligands expressed on NK sensitive YAC-1 cell line, viz., p30CA, p12, p15MA, p15E and NK resistant p815 cell line namely, Galectin-3, CD63 (AD1 Antigen), gp70 and p30 were studied.

The following information about p30CA (Accession no.= NP_955585.1, 263 amino acids, of Moloneymurine leukemia virus origin), p12 (Accession no.= 0804277A, 84 amino acids, of Moloneymurine leukemia virus origin), p15MA (Accession no.= NP_955583.1, 130 amino acids, of Moloneymurine leukemia Virus origin), p15E (Accession no.= NP_955589.1, 196 amino acids, of Moloneymurine leukemia virus origin) and Galectin-3 (Accession no. NP_034835.1), 264 amino acids of MusMusculus origin), CD63 (Accession no. NP_001036045.1), 238 amino acids of MusMusculus origin), gp70 (Accession no. CAA41992.1), 644 amino acids of Murine Leukemia Virus, p30 (Accession no. AAA46522.1), 160 amino acids of Murine Leukemia Virus were retrieved from NCBI. The crystallized structure of above mentioned ligands were not available in RCSB Protein Data Bank , so the structure of these ligands were modeled using a hybrid modeling server named Phyre2. The platform incorporates into folding simulation called Poing2to model regions of proteins with no detectable homology to the known structure [7-10].

Molecular docking using patchdock (an automatic server for molecular docking)

Patch Dock is an algorithm used for molecular docking. Here, the input is two molecules of any type e.g., proteins, DNA, drugs. The output obtained is a list of potential complexes that are sorted by the shape complementarity criteria. The Patch Dock algorithm has been inspired by image segmentation and object recognition techniques that are used in Computer Vision. If two molecules are given, then their surfaces are divided into patches depending upon the surface shape. These patches correspond to the patterns that distinguish between the puzzle pieces. Once these patches are identified and then they can be superimposed using the shape matching algorithms (Figure 1). The algorithm has three main stages:

• Molecular Shape Representation 
• Surface Patch Matching 
• Filtering and Scoring

The receptor molecule along with its ligand molecule was uploaded in the PATCHDOCK server, the respective e-mail id was entered and then the results were noted (Figure 2,3).

Refining models by FIREDOCK

After running PATCHDOCK, the top 10 results were refined by using FIREDOCK. The FireDock server then addresses refinement problem of the protein-protein docking solutions. This method simultaneously targets problem of flexibility along with the scoring of solutions that are produced by fast rigid-body docking algorithms. Given up to a set of 1000 potential docking candidates, it can refine and score them based on energy function. This is the first web server that allows scoring of docking solutions and performing large-scale flexible refinement online (Figure 4,5). The results with hydrogen bonds, the D COMPLEX predict the binding affinity of the protein complex, determining the energy in kcal/mol.

RESULTS

3D structure of NK activating receptor Ly49H

The 3D structure of NK activating receptor Ly49H is not available in PDB, so it was predicted using hybrid modeling server named Phyre2 (Figure 6) [11,12].

Structures of NK inhibitory receptor Ly49A

The crystal structure of Ly49A was not available on PDB, so the protein was modeled using a hybrid modeling server named Phyre2 (Figure 7).

Predicted structure of YAC-1 surface ligands

For all the YAC-1 surface ligands including, p30CA, p12, p15MA, p15E, the structures were not present in PDB. So the structures were also predicted with Phyre 2 (Figure 8: A-D).

Predicted structure of P815 surface ligands

The structures of CD63, galectin-3, p30, gp70, these are the p815 surface expressed molecules were not available in PDB so, the protein structures were modeled using a hybrid modeling server named Phyre 2 (Figure 9: A-D) (Table 1).

Predicted structure of P815 surface ligands

The structures of CD63, galectin-3, p30, gp70, these are the p815 surface expressed molecules were not available in PDB so, the protein structures were modeled using a hybrid modeling server named Phyre 2 (Figure 9: A-D) (Table 1).

Ly49H-p15E

The results obtained after docking of receptor Ly49H with p15E were observed. For each complex obtained, following data was analyzed. Here, the complex with minimum energy is the second one with D-complex energy -12.518432Kcal/mol and the complex representing minimum energy is shown below (Figure 10) (Table 2).

Ly49H-p30CA

The complex with minimum energy is the first one as depicted in Table (3) with D-complex energy - 11.061380 Kcal/ mol and the complex representing minimum energy is shown in (Table 3) (Figure 11).

Ly49H-p15MA

The complex with minimum energy is the first one as depicted in Table (4) with D-complex energy - 12.205013 Kcal/mol and the complex representing minimum energy is shown in Table (4) (Figure 12).

Ly49H-p12

The complex with minimum energy is the tenth one as depicted in Table (5) with D-complex energy - 8.455273 Kcal/ mol and the complex representing minimum energy is shown in Table (5) (Figure 13).

To understand the interaction between Ly49H, activating receptor (chain-X) and the ligands (chain-Y) present (p15E, p30CA, p15MA, p12) on the surface of YAC-1 cell line, docking was performed and the D-complex energies for each receptor– ligand pair was studied. The result shows significant interaction between each of the YAC ligands with Ly49H.

MURINE NK INHIBITORY RECEPTOR INTERACTION STUDIED WITH SURFACE LIGANDS OF P815

PATCHDOCK was used to perform molecular docking of murine inhibitory surface receptor Ly49A with the surface

PATCHDOCK was used to perform molecular docking Ly49H with the YAC-1 ligands; p15E, p30CA, p15MA, p12. PATCHDOCK determines top 10 complexes and for each of the complexes, the D-complex energy was calculated.

Ly49H-p15E

The results obtained after docking of receptor Ly49H with p15E were observed. For each complex obtained, following data was analyzed. Here, the complex with minimum energy is the second one with D-complex energy -12.518432Kcal/mol and the complex representing minimum energy is shown below (Figure 10) (Table 2).

Ly49H-p30CA

The complex with minimum energy is the first one as depicted in Table (3) with D-complex energy - 11.061380 Kcal/ mol and the complex representing minimum energy is shown in (Table 3) (Figure 11).

Ly49H-p15MA

The complex with minimum energy is the first one as depicted in Table (4) with D-complex energy - 12.205013 Kcal/mol and the complex representing minimum energy is shown in Table (4) (Figure 12).

Ly49H-p12

The complex with minimum energy is the tenth one as depicted in Table (5) with D-complex energy - 8.455273 Kcal/ mol and the complex representing minimum energy is shown in Table (5) (Figure 13).

To understand the interaction between Ly49H, activating receptor (chain-X) and the ligands (chain-Y) present (p15E, p30CA, p15MA, p12) on the surface of YAC-1 cell line, docking was performed and the D-complex energies for each receptor– ligand pair was studied. The result shows significant interaction between each of the YAC ligands with Ly49H.

Ly49A-gp70 The results obtained after docking of receptor Ly49A with gp70 were observed. For each complex obtained, following data was analyzed (Table 9) (Figure 17). Here, the complex with minimum energy is the first one with D-complex energy -11.879547 Kcal/mol and the complex representing minimum energy is shown above.

Table 1: p815 surface expressed ligands.

Ligand name Origin Structure availability
CD63 MusMusculus origin Modelled using Phyre2
Galectin-3 MusMusculus origin Modelled using Phyre2
p30 Murine Leukemia Virus Modelled using Phyre2
gp70 Murine Leukemia Virus Modelled using Phyre2

Table 2: Representing minimum energy for Ly49H-p15E.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 8 13004 1881.30 -7.958298
2 4 13288 1675.50 -12.518432
3 7 13020 1616.00 -6.078592
4 9 12956 1633.40 -6.998742
5 3 13386 1682.20 -3.906250
6 2 13428 1888.20 -6.315068
7 6 13076 1646.50 -6.355111
8 1 14584 1805.30 -11.026176
9 5 13094 1535.10 8.240053
10 10 12906 2309.30 -6.856760

Table 3: Representing minimum energy Ly49H-p30CA.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 10 12816 1782.60 -11.061380
2 1 15552 2125.10 -11.043210
3 3 13640 2610.20 3.583099
4 9 12842 1828.80 -6.233670
5 8 12864 1538.10 -10.211391
6 2 14556 1712.60 -10.105183
7 7 12866 1910.70 -6.869576
8 6 13456 2312.60 -4.854557
9 5 13596 1979.00 -8.113094
10 4 13596 2295.70 -4.700000

Table 4: Representing minimum energy Ly49H-p30CA.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 3 13172 1629.80 -12.205013
2 8 12380 1610.70 -7.548349
3 9 12376 1735.30 -9.758832
4 10 12344 2049.90 -3.523870
5 4 12922 2142.90 -10.070923
6 1 13532 2317.30 -3.179320
7 6 12582 2069.70 -4.670235
8 5 12630 1824.10 -4.355385
9 2 13396 1937.70 10.206377
10 7 12444 1942.00 -4.854555

Table 5: Representing minimum energy Ly49H-p12.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 4 11670 1548.10 -7.701501
2 7 11378 1659.40 -8.169250
3 10 11220 1631.30 -4.092175
4 2 12534 1759.70 -8.218939
5 9 11258 1641.80 -6.653870
6 5 11626 1527.90 -5.149787
7 3 11872 1649.40 -3.852422
8 1 12808 1783.50 -4.707519
9 8 11366 1673.60 -6.188818
10 6 11378 1796.90 -8.455273

Table 6: D-complex energies for Ly49A forLy49A-CD63.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 1 14340 2093.20 -6.579559
2 2 14216 2164.10 -4.585131
3 9 12984 2185.50 -4.631744
4 3 13956 1819.70 -5.695937
5 7 13122 2285.50 -4.70000
6 4 13836 1727.90 -5.003655
7 8 13106 2010.20 -5.607669
8 10 12824 1805.30 -3.485970
9 6 13400 2101.20 -1.997861
10 5 13614 2330.20 -4.003188

Table 7: D-complex energies for Ly49A-galectin-3.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 9 11398 1536.50 -9.467794
2 6 11676 1734.10 -6.930770
3 7 11504 1633.90 111.539484
4 8 11450 1461.90 -8.500221
5 2 12374 1586.70 -5.118127
6 4 11804 1579.70 -6.278455
7 1 13150 2039.50 -7.149738
8 3 12266 1512.70 -10.283447
9 10 11382 1884.30 -4.452348
10 5 11758 1774.90 -4.745952

 

DISCUSSION

The evasion of tumors in spite of host immune defenses is by the interaction of various tumor ligands with their receptors on immune cells that affects the function of host cells involved in immune responses. So, different tumor-derived factors or ligands may affect the function of natural killer (NK) cells by upregulatory and down-regulatory modulation of receptors [4].

The present study aimed at identifying the multiple factors derived from NK sensitive cell line (YAC-1) and NK resistant cell line (P815) that might be involved in bringing about changes in the NK cytotoxicity outcome. Ly49H is a prototypic activating receptor while Ly49A has been taken as a prototypic inhibitory receptors found in mouse NK cells. Sequences of respective ligands from YAC-1 and P815 cells were obtained from NCBI. Further, PATCHDOCK was used to perform molecular docking of Ly49H with the YAC-1 ligands and Ly49A with P815 ligands.

PATCHDOCK determines top 10 complexes for each of the ligandreceptor complexes from which the D-complex energy was calculated.

The ligands expressed by YAC tumor cells p30CA,p12,p15MA and p15E show significant binding efficiency with Ly49H and the ligands expressed by P815 cells line galactin-3,CD63 (AD1 antigen),gp70 and p30show significant binding efficiency with Ly49A.

Our study provides direct evidence that in case of YAC1 cell line which was known to show susceptibility to NK cytotoxicity owing to its low level of expression of MHC I thus preventing engagement of inhibitory receptors on NK cells is not the only reason for its susceptibility. Yac1 cell expressed ligands, p30CA, p12, p15MA and p15E all show significant binding to activating NK cell receptor thus leading to activation signal transduction for cytotoxicity.

P815 cell line known to be resistant to NK cell mediated cytotoxicity has been known to express high levels of MHCI and hence engage inhibitory receptors on NK cells resulting in escape from NK mediated killing. However, in the present study, we have also shown that P815 expressed ligands galactin-3,CD63 (AD1 antigen),gp70 and p30, all show direct significant binding to inhibitory Ly 49 receptor thus providing direct evidence that engagement of tumor expressed ligands by inhibitory receptors are significant in providing resistance of P815 from NK mediated cell lysis.

Table 8: D-complex energies for Ly49A-p30.

 

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 7 11666 1424.20 -7.158205
2 2 12416 1508.90 -11.074407
3 8 11572 1458.00 -6.778593
4 6 11796 1786.60 24.503307
5 3 12182 2217.50 -2.055967
6 1 12634 2205.30 -4.072277
7 4 11902 1621.60 -4.70000
8 5 11842 1753.60 -4.519311
9 9 11508 1378.70 -5.943563
10 10 11504 1664.90 -4.636067

Table 9: D-complex energies for Ly49A-gp7.

Rank Solution 
no.
Score Area D-complex
(kcal/mol)
1 4 1326 2245.00 -11.879547
2 1 14438 1899.30 -3268851
3 8 13022 1804.90 -8.566955
4 2 13964 1872.50 -5.879165
5 7 13092 1835.20 -5.508979
6 6 13238 1989.30 -8.161250
7 5 13384 1838.60 -3.141820
8 9 12904 1721.20 -4.220493
9 3 13920 2097.80 -5.034545
10 10 12840 2833.60 9.995013
CONCLUSION

Killing of tumor cells by NK cells is a dynamic interaction and signaling process in which binding of activating ligands to NK activating receptors induce target cell mediated killing by initiating cascade of signaling reactions resulting in cytolysis by NK cells. Susceptibility of tumor cells to NK may often be due to reduced engagement of inhibitory receptors by down regulation of MHC I ligand for NK inhibitory receptors. However in case of YAC-1 cells, we have shown conclusively that it is not only down regulation of inhibitory signal that results in activation but direct engagement of activating receptors by tumor expressed ligands on YAC-1 cells results in upregulation of activation signals in NK resulting in susceptibility of YAC cells to NK mediated cytotoxicity. In case of NK resistant cell line, P815 engagement of specific tumor expressed ligands by inhibitory receptors in NK cells results in interference of the activating signaling cascade resulting in target cell being spared by NK cells. Each NK cell expresses a multitude of activating and inhibitory receptors. The sum total of these opposing signals results in the outcome of the NK target interaction.

In the present study, surface expressed molecules present on p815 and YAC-1 cells were studied for binding with inhibitory receptors and activating receptors respectively. The results obtained show that the binding affinities obtained with docking of murine NK inhibitory receptor Ly49A with the surface ligands of mastocytoma p815 were quite significant (CD63 with -6.579559, galectin-3 having -10.283447, p30 with -11.074407 and gp70 having -11.879547 binding affinities) this tumor is itself known to modulate NK by changing the receptor profile of it and hence, further increasing the inhibition. Multiple inhibitory ligands were engaged by p815 cells and further studies need to be carried out whether these ligands of NK resistant cell line cause modulations in inhibitory receptor profiling, while docking results of NK activating receptor Ly49H with the surface ligands of T-lymphoma YAC-1 were also significantly marked (p15E with -12.518432, p30CA with -11.061380, p15MA with -12.205013 and p12 with -8.455272), which activate the NK effector function and tumor cells could not resist themselves anymore and thus are killed.

In the same way, other important surface proteins can be taken in future studies like Moloney leukemia virus-determined cell surface antigen (MCSA) [5], NKTS [6], p71 [5,6,13-15], H-2a , etc., once their sequences are deduced.

In the present studies we tried to elucidate the molecular basis of susceptibility of YAC tumor cells and resistance of P815 cells to NK mediated cytotoxicity.

 

ACKNOWLEDGMENTS

We are grateful to Department of Science and Technology, SERB Young Scientist Award which supported the present work. All the present work was done in Delhi Technological University, Department of Biotechnology.

REFERENCES

1. Zucchini N, Crozat K, Baranek T, Robbins SH, Altfeld M, Dalod M. Natural killer cells in immunodefense against infective agents. Expert Rev Anti Infect Ther. 2008; 6: 867-885.

2. Jonji? S, Babi? M, Poli? B, Krmpoti? A. Immune evasion of natural killer cells by viruses. Curr Opin Immunol. 2008; 20: 30-38.

3. Roder JC, Kiessling R, Biberfeld P, Andersson B. Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol. 1978; 121: 2509-2517.

4. Nelson DS, Nelson M. Evasion of host defences by tumours. Immunol Cell Biol. 1987; 65: 287-304.

5. Troy FA, Fenyg EM, Klein G. Moloney leukemia virus-induced cell surface antigen: Detection and characterization in sodium dodecyl sulfate gels. Proc Nati Acad Sci USA. 1977; 74: 5270-5274.

6. Roder JC, Rosén A, Fenyö EM, Troy FA. Target-effector interaction in the natural killer cell system: isolation of target structures. Proc Natl Acad Sci USA. 1979; 76: 1405-1409.

7. Cortegano I, del Pozo V, Cárdaba B, de Andrés B, Gallardo S, del Amo A, et al. Galectin-3 down-regulates IL-5 gene expression on different cell types. J Immunol. 1998; 161: 385-389.

8. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011; 17: 6985-6991.

9. Dorfman JR, Raulet DH. Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med. 1998; 187: 609-618.

10. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res. 2003; 9: 2374- 2383.

11. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999; 17: 875-904.

12. Lopez DM, Lopez-Cepero M, Watson GA, Ganju A, Sotomayor E, Fu YX. Modulation of the immune system by mammary tumor-derived factors. Cancer Invest. 1991; 9: 643-653.

13. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today. 2000; 21: 228-234.

14. Al-Rammahy AK, Levy JG, Jackson AL. Isolation and partial characterization of a tumor-associated antigen of the P815 mastocytoma of DBA/2 mice. J Immunol. 1980; 124: 143-150.

15. Roder JC, Ahrlund-Richter L, Jondal M. Target-effector interaction in the human and murine natural killer system: specificity and xenogeneic reactivity of the solubilized natural killer-target structure complex and its loss in a somatic cell hybrid. J Exp Med. 1979; 150: 471-481.

Received : 26 Aug 2016
Accepted : 12 Nov 2016
Published : 16 Nov 2016
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X